• Keine Ergebnisse gefunden

Literaturverzeichnis zum Titelthema „Prävention in der Frauenheilkunde; Was ist gesichert – was ist Mythos?“ Bayerisches Ärzteblatt 4/2013, Seite 144 f. von Professor Dr. Birgit Seelbach-Göbel

N/A
N/A
Protected

Academic year: 2022

Aktie "Literaturverzeichnis zum Titelthema „Prävention in der Frauenheilkunde; Was ist gesichert – was ist Mythos?“ Bayerisches Ärzteblatt 4/2013, Seite 144 f. von Professor Dr. Birgit Seelbach-Göbel"

Copied!
2
0
0

Wird geladen.... (Jetzt Volltext ansehen)

Volltext

(1)

Literaturverzeichnis

zum Titelthema „Prävention in der Frauenheilkunde; Was ist gesichert – was ist Mythos?“

Bayerisches Ärzteblatt 4/2013, Seite 144 f.

von Professor Dr. Birgit Seelbach-Göbel

1. www.bmg.de

2. Donovan B et al: Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis, 2011 Jan; 11 (1):39-44

3. GØtsche PC, Nielsen M: Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2011 Jan 19; (1): CD001877

4. Hofvind S, Lee Cl, Elmore JG: Stage-specific breast cancer incidence rates among participants and non-participants of a population-based mammographic screening Programm. Breast Cancer Res Treat., 2012 Aug; 135 (1):291-9

5. Bleyer A, Welch HG: Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med; 2012 Nov 22; 367(21): 1998-2005

6. Marmot MG et al: The benefits and harms of breast cancer screening: an independent review. Lancet. 2012 Nov 17; 380(9855):1778-86

7. Buys et al: Effect of screening on ovarian cancer mortality: the Prostate, Lung,

Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011 Jun 8;305(22):2295-303

8. Schnell-Inderst et al: Individual health services. GMS Health Technol Assess.2011;7:Doc05 9. Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des

Mammakarzinoms. Juli 2012, AWMF- Register-Nummer: 032-045OL

10. Burges A, Schmalfeldt B: Ovarialkarzinom: Diagnostik und Therapie. Dtsch. Ärzteblatt Int.2011; 108(38): 635-41

11. Cuzick J, Powles T, Veronesi U, Forbe J, Edwards R, Ashley s, Boyle P: Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003 Jan 25; 361(9345):296-300

12. Vogel V G et al: Effects of Tamoxifen vs Raloxifene ion the Risk of Developing invasive

Breast Cancer and Other Disease Outcomes. The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA. June 21, 2006- Vol 295, No. 23

13. Goss PE, Ingle JN, Alés-Martinez JE, Cheung AM, Chlebowski RT, Wactwawski- Wende J, et al: Exemestane for breast cancer prevention in postmenopausal women. N Engl J Med 2011; 364:2381-91

14. Uray IP, Brown PH: Chemoprevention of hormone receptor-negative breast cancer: new approaches needed. Recent Results Cancer Res. 2011; 188: 147-62

15. Hung HC et al: Fruit and Vegetable Intake and Risk of Major Chronic Disease. Journal of the National Cancer Institute, Vol. 96, No.21, November 3, 2004

16. Van Gils CH et al: Consumption of vegetables and fruits and risk of breast cancer.

JAMA 2005 Jan 12;293(2):183-93

17. Schulz M et al: Fruit and vegetable consumption and risk of epithelial ovarian cancer: the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol

Biomarkers Prev. 2005 Nov; 14(11 Pt 1):2531-5

18. Bjelakovic G, Nikolova D, Gluud L, Simonetti R G, Gluud C,: Mortality in

Randomized trials of Antioxidant Supplements for Primary and Secondary Prevention.

Systematic Review ND Meta-analysis. JAMA, 2007; 297(8): 842-857

19. Klein E et al: Vitamin E and the Risk Prostate Cancer. The Selenium and Vitamin E Cancer Prevention Trial (SELECT)

20. Dennert G, Zwahlen M, Brinkman M, Vinceti M, Zeegers MP, Horneber M: Selenium for preventing cancer. Cochrane Database Syst Rev. 2011 May 11; (5): CD005195 21. Lin J et al: Vitamins E and E and Beta Carotene Supplementation and Cancer Risk:

A Randomized Controlled Trial. J Natl Cancer Inst. 2009 Jan 7; 101 (1): 14-23

22. Hercberg S et al: Incidence of cancers, ischemic cardiovascular diseases and mortality during 5-year follow-up after stopping antioxidant vitamins and minerals supplements:

a postintervention follow-up in the SU.VI.MAX Study. International Journal of Cancer:

127, 1875-1881 (2012)

23. Andreeva V et al: B Vitamin and /or ω-3 Fatty Acid Supplementation and Cancer.

Ancillary Findings From the Supplementation With Folate, Vitamins B₆ and B₁₂ and/or

(2)

Literaturverzeichnis

zum Titelthema „Prävention in der Frauenheilkunde; Was ist gesichert – was ist Mythos?“

Bayerisches Ärzteblatt 4/2013, Seite 144 f.

von Professor Dr. Birgit Seelbach-Göbel

Omega- 3 Fatty Acids (SU. FOL. OM3) Randomized Trial. Arch Intern Med. 2012 Apr 9: 172(7): 540-7

24. Helzlsouer K for the VDPP Steering Committee: Overview of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. American Journal of Epidemiology. June 18, 2010. Vol. 172, No.1

25. Garland CF et al: Vitamin D and prevention of breast cancer: Pooled analysis.

The Journal of Steroid Biochemistry & Molecular Biology. Journal of Steroid Biochemistry & Molecular Biology 103 (2007) 708-711

26. Abbas S et al: Serum 25-hydroxyvitamin D and risk of post-menopausal breast

cancer- results of a large case-control study. Carcinogenesis vol.29 no. 1 pp.93-99, 2008 27. Bilinski K, Boyages J: Association between 25-hydroxyvitamin D concentration and

breast cancer risk in an Australian population: an observational case-control study.

Brest Cancer Res Treat. 2013 Jan; 137 (2):559-607

28. Autier P, Gandini S: Vitamin D Supplementation and Total Mortality. Arch Intern Med.

Vol 167 No.16, Sep 10, 2007

29. Lappe J, Travers-Gustafson D, Davies K, Recker R, Heaney R: Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 2007;

85:1586-91

30. Chlebowski R et al: Health Initiative Investigators: Calcium Plus Vitamin D

Supplements and the Risk of Brest Cancer. J Natl Cancer Inst, 2007; 100: 1581-1591 31. Zeeb H, Greinert R: Bedeutung von Vitamin D in der Krebsprävention.

Dtsch Ärztebl Int. 2010; 107(37):638-43

32. Deutsche Gesellschaft für Gynäkologie und Geburtshilfe: Interdisziplinäre S 3-Leitlinie- AWMF 015/062. Stand September 2009

33. Levis S et al: Soy Isoflavones in the Prevention of Menopausal Bone Loss and Menopausal Symptoms. A Randomized, Double-blind trial. Arch Intern Med/Vol 171 (No.15), Aug 8/22 2011 34. Yamamoto S, Sobue T, Kobayashi M, Sasaki S, Tsugane S; Japan Public Health Center-Based

Prospective Study on Cancer Cardiovascular Diseases Group: Soy, isoflavones, and breast cancer

risk in Japan. J Natl Cancer Ist. 2003 Jun 18; 95 (12): 906-13

35. Verheus M, van Gils CH, Keinan-Boker L, Grace PB, Bingham SA, Peeters PH: Plasma phytoestrogens and subsequent breast cancer risk. J Clin Oncol. 2007 Feb 20; 25(&):648-55 36. Ward HA, Kuhnle GG, Mulligan AA, Lentjes MA, Luben RN, Khaw KT:

Breast, colorectal, and prostate cancer risk in the European Prospective investigation into Cancer and Nutrition-Norfolk in relation to phytoestrogen intake derived from an Improved database.

Am J Clin Nutr. 2010 Feb; 91(2):440-8

37. Bandera EV et al: Phytoestrogen consumption and endometrial cancer risk: a population-based case-control study in New Jersey. Cancer Causes Control. 2009 Sep; 20(7):1117-27

38. Leitzmann M et al: Prospective study of physical activity and risk of menopausal breast cancer.

Breast Cancer Research 2008, 10:R92, published: 31 October 2008

Referenzen

ÄHNLICHE DOKUMENTE

Global Initiative for Chronic Obstructive Lung Disease: Global Strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease.. Murray CJ,

[5] Rydén L, Grant PJ, Anker SD, Berne C et al., ESC Guidelines on diabetes, pre- diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force

Screening for Prostate Cancer: A Guidance Statement from the Clinical Guidelines Committee of the American College of Physicians.. Ann

BZgA, Bundeszentrale für gesundheitliche Aufklärung (2013): Materialien zur Suchtprävention.. – Wir Kinder vom

Decreasing incidence of occupational contact urticaria caused by natural rubber latex allergy in German health care workers.. Dickel H, Kuss O, Schmidt A,

Bundesärztekammer, Arzneimittelkommission der deutschen Ärzteschaft, Deutsche Diabetes Gesellschaft et al.. (2003) Nationale Versorgungs-Leitlinie Diabetes mellitus Typ

Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, Adriaenssens T, Vrolix M, Heestermans AA, Vis MM, Tijsen JG, van 't Hof AW, ten Berg JM; WOEST

Prevalence, incidence and obstetric factors' impact on female urinary incontinence in Europe: a systematic review.. Quality of life and urinary incontinence